Paper of the month
-
30.04.2022 April 2022: Adjuvant pertuzumab significantly improved invasive disease-free survival for HER2-positive, N-positive early breast cancer in the APHINITY trial
We are pleased to inform you that a STEPP analysis of the updated data from the APHINITY trial has been published in European Journal of Cancer
-
31.03.2022 March 2022: Long-term outcomes from the BrighTNess trial support inclusion of carboplatin in neoadjuvant chemotherapy for early-stage TNBC.
We are pleased to inform you that 4-year follow-up data from the BrighTNess trial has been published in Annals of Oncology.
-
28.02.2022 February 2022: Effects of capecitabine as part of neo-/adjuvant chemotherapy
We are pleased to inform you that a meta-analysis of capecitabine effect as part of neo-/adjuvant chemotherapy including 15,993 patients from 13 randomized trials has been published in European Journal of Cancer.
-
31.01.2022 January 2022: pCR in the breast and axillary lymph nodes correlates with iDFS – results from GeparOcto trial
We are pleased to inform you that an exploratory analysis of the randomized phase III GrparOcto trial has been published in Cancer
-
31.12.2021 December 2021: mdm2 gene amplification in luminal breast cancer
A biomarker analysis in luminal breast cancer using a humanized tumor mouse (HTM) model has been published in International Journal of Cancer.